http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022145949-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbffa3b81b3b862dc7220b5648f5f745 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2021-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e21bbb15fdc9a05af0343336ba7024c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1285d2d304003963aba13e85dba783e |
| publicationDate | 2022-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022145949-A2 |
| titleOfInvention | Composition comprising tead4 inhibitor for preventing or treating colorectal cancer |
| abstract | The present invention relates to a composition for preventing or treating colorectal cancer. The TEAD4 inhibitor of the present invention can revert the gene expression of colorectal cancer in an early stage to a gene expression pattern similar to that in differentiated normal colorectal cells to treat colorectal cancer in an early stage and when used in combination with an ELK1 inhibitor, can revert the gene expression of malignant colorectal cancer to a gene expression pattern similar to that in normal colorectal cells, thereby finding advantageous applications in the prophylactic and therapeutic field of colorectal cancer. |
| priorityDate | 2020-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 418.